223 related articles for article (PubMed ID: 23334403)
1. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
Hoch M; Hoever P; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Jun; 69(6):1235-45. PubMed ID: 23334403
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
[TBL] [Abstract][Full Text] [Related]
3. Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882.
Dingemanse J; Nicolas LB; van Bortel L
Eur J Clin Pharmacol; 2014 Jun; 70(6):675-84. PubMed ID: 24728182
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers.
Teng R; Mitchell PD; Butler KA
Eur J Clin Pharmacol; 2013 Mar; 69(3):477-87. PubMed ID: 22922682
[TBL] [Abstract][Full Text] [Related]
5. Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.
Kokudai M; Inui N; Takeuchi K; Sakaeda T; Kagawa Y; Watanabe H
J Clin Pharmacol; 2009 May; 49(5):568-73. PubMed ID: 19398603
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
[TBL] [Abstract][Full Text] [Related]
7. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
Gerber JG; Rosenkranz SL; Fichtenbaum CJ; Vega JM; Yang A; Alston BL; Brobst SW; Segal Y; Aberg JA;
J Acquir Immune Defic Syndr; 2005 Jul; 39(3):307-12. PubMed ID: 15980690
[TBL] [Abstract][Full Text] [Related]
8. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.
Shin J; Pauly DF; Pacanowski MA; Langaee T; Frye RF; Johnson JA
Pharmacotherapy; 2011 Oct; 31(10):942-50. PubMed ID: 21950641
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
10. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.
Polli JW; Hussey E; Bush M; Generaux G; Smith G; Collins D; McMullen S; Turner N; Nunez DJ
Xenobiotica; 2013 Jun; 43(6):498-508. PubMed ID: 23256625
[TBL] [Abstract][Full Text] [Related]
12. Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Piscitelli S; Kim J; Gould E; Lou Y; White S; de Serres M; Johnson M; Zhou XJ; Pietropaolo K; Mayers D
Br J Clin Pharmacol; 2012 Aug; 74(2):336-45. PubMed ID: 22288567
[TBL] [Abstract][Full Text] [Related]
13. Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects.
Falcão A; Pinto R; Nunes T; Soares-da-Silva P
Epilepsy Res; 2013 Sep; 106(1-2):244-9. PubMed ID: 23726291
[TBL] [Abstract][Full Text] [Related]
14. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.
Molden E; Skovlund E; Braathen P
Drug Saf; 2008; 31(7):587-96. PubMed ID: 18558792
[TBL] [Abstract][Full Text] [Related]
15. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.
Bakhai A; Rigney U; Hollis S; Emmas C
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927
[TBL] [Abstract][Full Text] [Related]
17. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
[TBL] [Abstract][Full Text] [Related]
18. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Oct; 68(4):384-90. PubMed ID: 11061578
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem.
Dingemanse J; Cruz HG; Gehin M; Hoever P
J Pharm Sci; 2014 May; 103(5):1548-56. PubMed ID: 24604243
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.
Hulskotte EG; Feng HP; Xuan F; Gupta S; van Zutven MG; O'Mara E; Wagner JA; Butterton JR
Antimicrob Agents Chemother; 2013 Jun; 57(6):2582-8. PubMed ID: 23529734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]